Comparison · NCT01520909-b38ee084
Part 1 (Randomized Period)-Eltrombopag vs Part 1 (Randomized Period)- Placebo: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part 1 (Randomized Period)-Eltrombopag vs Part 1 (Randomized Period)- Placebo: Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1. Trial comparisons, record NCT01520909-b38ee084. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01520909-b38ee084
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.397 | 0.285 | 0.52 | wilson | |
| Risk in group 2 | 0.0345 | 0.00611 | 0.172 | wilson | |
| Risk difference, group 1 minus group 2 | 0.362 | 0.185 | 0.489 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 11.5 | 1.64 | 80.9 | log | |
| Odds ratio, group 1 over group 2 | 18.4 | 2.35 | 144 | log | |
| Number needed to treat, for one more participant with the outcome on Part 1 (Randomized Period)-Eltrombopag than on Part 1 (Randomized Period)- Placebo | 2.76 | 2.05 | 5.39 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part 1 (Randomized Period)-Eltrombopag | In Part 1, participants aged between 6 and 17 years with a body weight \<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day. | 25 | 63 | OG001 |
| Group 2 | Part 1 (Randomized Period)- Placebo | In Part 1, participants aged between 6 and 17 years with a body weight \<27 kilograms (kg) received placebo 37.5 milligrams (mg) once daily (QD), and those with a body weight \>=27 kg received placebo 50 mg QD. Participants of East Asian ancestry received a starting dose of placebo 25 mg QD. Participants aged between 1 and 5 years received placebo 1.2 milligrams per kilogram (mg/kg) QD; participants of East Asian ancestry received a starting dose of placebo 0.8 milligrams per kilograms per day (mg/kg/day). | 1 | 29 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1
- Description
- Participants who achieved a platelet count \>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.
- Time frame
- From Week 5 up to Week 12 of Part 1
- Population
- Intent-to-Treat (ITT) Population: all randomized participants. The ITT Population was the primary population used for assessing efficacy.
Source ClinicalTrials.gov
Trial
- Title
- Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
- NCT number
- NCT01520909
- Phases
- PHASE3
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Eltrombopag, Placebo
- Lead sponsor
- GlaxoSmithKline
- Results first posted
- 2014-09-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01520909?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01520909-b38ee084